The gastritis treatment market has been growing significantly owing to the increasing prevalence of gastritis disorder globally. Gastritis is inflammation of the stomach lining that may occur as a short episode or persist for years. Common symptoms include abdominal pain, nausea, bloating, and loss of appetite. The market comprises products such as antacids, H2 blockers, proton pump inhibitors, and others that prevent and treat symptoms of gastritis. The need for effective gastritis treatment is rising with the growing number of patients diagnosed with the disorder each year.
The global gastritis treatment market is estimated to be valued at US$ 131.76 billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period of 2023 to 2030. Key factors such as sedentary lifestyles, alcohol consumption, and consumption of painkillers that can irritate the stomach lining contribute to the high prevalence of gastritis. Several pharmaceutical companies are developing new drug formulations and combinations to enhance treatment effectiveness and offer sustainable relief from gastritis symptoms.
Key Takeaways
Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson Johnson, Novartis AG, and Takeda Pharmaceutical Company Limited. These players are strongly focused on research and development activities to launch advanced treatment options for gastritis.
There are significant opportunities for companies in the areas of combination drug therapies, convenient dosage forms such as orally disintegrating tablets, and drugs with fewer gastrointestinal side effects than existing therapies. Large pharmaceutical companies are expanding their geographic presence into emerging markets through partnerships with local players.
Global expansion remains a key strategy for top players in the gastritis treatment market. Companies are strengthening their distribution networks across Asia Pacific, Latin America, Middle East, and Africa where the prevalence of gastritis is progressively increasing.
Market Drivers
One of the major drivers for the gastritis treatment market is the growing global disease burden of gastritis. Various risk factors associated with modern lifestyles such as high stress levels, unhealthy diets, and alcohol consumption are contributing to the increasing prevalence of gastritis worldwide. According to the Global Burden of Disease Study, gastritis accounted for approximately 1.87% of the total global disease burden in 2019 in terms of years lived with disability. The growing disease prevalence is driving the demand for therapeutic drugs and treatment regimens.
Market Restraints
A key restraint for the gastritis treatment market's growth is the availability of alternative treatment methods and home remedies. For minorcases of gastritis, home remedies using antacids, lemon juice, licorice, etc. provide temporary relief from symptoms and are preferred by some patients due to their easy accessibility and avoidance of drug side effects. Strict regulatory norms regarding the approval of new drugs also pose challenges for pharmaceutical companies in terms of high development costs and delayed market entry compared to generics.
Segment Analysis
The gastritis treatment market can be segmented based on drug class, type, distribution channel, and geography. Based on drug class, the proton pump inhibitors dominated the market in 2023 due to their widespread usage for gastritis treatment. Proton pump inhibitors inhibit the production of gastric acid in cells lining the stomach and offer longer relief from acid-related stomach problems compared to H2 blockers or antacids. By type, the market is classified into erosive (acute) gastritis and non-erosive (chronic) gastritis. Erosive gastritis dominates the market as it requires prompt medical care and treatment to avoid further complications.
Global Analysis
North America holds the largest share in the gastritis treatment market and is expected to grow at a CAGR of 5.1% during the forecast period. Rising incidences of gastric ulcers and growing awareness about treatment options available drive market growth in the region. Europe is the second largest regional market due to increasing consumption of tobacco alcohol and growing geriatric population more susceptible to gastritis. However, Asia Pacific is expected to be the fastest growing market during the forecast period. The upsurge in healthcare expenditure, large patient pool, growing western influences on diet, and increase in lifestyle diseases boost market growth in Asia Pacific.